OncoMatch/Clinical Trials/NCT04585477
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Is NCT04585477 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including AVENIO ctDNA Surveillance Kit and Durvalumab for non-small cell lung cancer.
Treatment: AVENIO ctDNA Surveillance Kit · Durvalumab · Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy — In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR exon 19 deletion
Adenocarcinoma patients must NOT be positive for EGFR Exon 19 deletion or L858R mutation
Excluded: EGFR L858R
Adenocarcinoma patients must NOT be positive for EGFR Exon 19 deletion or L858R mutation
Excluded: ALK rearrangement
Adenocarcinoma patients must NOT be positive for ... ALK or ROS1 rearrangement
Excluded: ROS1 rearrangement
Adenocarcinoma patients must NOT be positive for ... ALK or ROS1 rearrangement
Disease stage
Required: Stage IA2, IB, IIA, IIB, IIIA, IIIB, IIIC (AJCC 8th edition)
Excluded: Stage IA1
AJCC 8th edition clinical or pathological stage IA2 to IIIC or locoregionally recurrent disease. Stage IA1 tumors are excluded unless recurrent with radiographic solid component -or- pathologic invasive component of > 10 mm.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — curative intent
Received curative intent therapy with surgery and/or radiation
Must have received: radiation therapy — curative intent
Received curative intent therapy with surgery and/or radiation
Cannot have received: immunotherapy (PD-1, PD-L1, or CTLA-4 antibodies)
Exception: apart from this study
Not received immunotherapy (PD-1, PD-L1, or CTLA-4 antibodies) or be intended to receive immunotherapy, apart from this study.
Cannot have received: systemic anti-cancer investigational product
Not received another systemic anti-cancer investigational product during the 4 weeks prior to enrollment.
Lab requirements
Blood counts
Absolute neutrophil count > 1.0 x 10^9/L; Platelets > 75 x 10^9/L; Hemoglobin ≥ 9.0 g/dL
Kidney function
Creatinine ≤ 1.5 x ULN; or measured creatinine clearance >40 mL/min; or calculated creatinine clearance >40 mL/min by Cockcroft-Gault formula
Liver function
Serum bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN
Acceptable laboratory parameters: Absolute neutrophil count > 1.0 x 10^9/L; Platelets > 75 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; Creatinine ≤ 1.5 x ULN; or Measured creatinine clearance (CL) >40 mL/min; or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula; Serum bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify